Autres langues Karyopharm Therapeutics Inc.

Actions

KPTI

US48576U1060

Temps Différé Nasdaq Autres places de cotation 21:49:46 03/05/2024			Varia. 5j.	Varia. 1 janv.
1,115 ^USD	+3,24%		+4,72%	+28,32%

24/04	Karyopharm Therapeutics Inc. annonce des présentations sur le cancer de l'endomètre et la myélofibrose lors de l'assemblée annuelle 2024 de l'American Society of Clinical Oncology	CI
13/03	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024	02/05
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting	25/04
Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	24/04
Karyopharm Therapeutics : April 19, 2024	19/04
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences	06/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	04/03
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress	01/03
Karyopharm Therapeutics: Q4 Earnings Snapshot	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Posts Q4 Revenue $33.7M, vs. Street Est of $33.6M	29/02
Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Year 2024	29/02
North American Morning Briefing : Fed's Preferred -2-	29/02
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024	22/02
North American Morning Briefing : Stock Futures -2-	21/02
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/02
Karyopharm Therapeutics Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Full Year 2023	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Karyopharm Therapeutics Inc.

Actions

KPTI

US48576U1060

Autres langues

Filtres